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The effects of intravenous captopril and intravenous dig 
oxin given separately and in combination on rest and 
exercise hemodynamics were studied in 16 patients with 
severe heart failure and sinus rhythm. When given sepa- 
rately, both captopril and digoxin decreased the pulmonary 
capillary wedge pressure by, respectively, 24% (p = 0.003) 
and 34% (p = 0.004) and systemic vascular resistance by 
23% (p = 0.09) and 20% (p = 0.03). Only digoxin 
increased cardiac index by 23% (p = 0.03) and stroke work 
index by 52% (p = 0.01). 
During maximal exercise, captopril alone decreased 
systemic vascular resistance by 28% (p = 0.0002) and 
increased cardiac index by 33% (p = 0.02). Digoxin alone 
decreased pulmonary capillary wedge pressure by 11% (p 
= 0.04) and increased stroke work index by 44% (p = 
0.01). The combination of captopril and digoxin resulted in 
a decrease in pulmonary capillary wedge pressure and 
systemic vascular resistance and an increase in cardiac 
index and stroke work index both at rest and during 
exercise that was greater than values observed with either 
drug given alone. 
Cardiac index response to the combination of captopril 
and digoxin correlated with baseline serum aldosterone 
concentration (r = 0.81, p < 0.001) and plasma renin 
activity (r = 0.74, p < 0.0002). A significant decrease in 
norepinephrine concentration was noted after digoxin was 
administered alone or added to captopril. 
These findings demonstrate that in patients with severe 
heart failure, the acute administration of captopril and 
digoxin has an independent salutary hemodynamic effect. 
The combination of these agents, however, has an adjunc- 
tive effect on cardiac function at rest and during exercise. 
(J Am Co11 Cardiol1989;13:134-42) 
The role of digitalis preparations in the treatment of patients angiotensin-converting enzyme inhibitors in patients with 
with heart failure and sinus rhythm remains controversial heart failure who were maintained on digoxin therapy dem- 
(1,2). Because of the increased systemic vasoconstriction onstrated both hemodynamic and clinical benefit. A recent 
occasionally seen with the use of a cardiac glycoside, its double-blind study (18) concluded that both captopril and 
inotropic effect may not always be translated into a benefi- digoxin, when used separately, were useful in patients with 
cial hemodynamic or clinical response (3-7). Angiotensin- heart failure; however, only digoxin significantly increased 
converting enzyme inhibitors improve cardiac function by the ejection fraction when compared with captopril, and only 
reducing both arterial and venous resistance (8,9) by atten- captopril resulted in a significant increase in exercise time 
uating the neurohormonal imbalance observed in heart fail- and improvement in functional class when compared with 
ure (10). During the last decade, clinical studies (11-17) of results after placebo. 
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Because angiotensin-converting enzyme inhibitors (in 
particular, captopril) prevent some of the peripheral vaso- 
constrictive effects of digitalis preparations (19), it is possi- 
ble that the combination of digoxin and captopril may be 
more beneficial in the treatment of heart failure than is either 
drug used alone. This study examines the hemodynamic and 
neurohormonal effects of the intravenous administration of 
these agents given separately and in combination to patients 
with severe heart failure and sinus rhythm. 
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Table 1. Clinical Characteristics and Baseline Hemodynamics in 16 Patients 
Patient Age iyr) & 
No. Gender 
Etiology of 
Heart Failure 
NYHA 
Prior Therapy” 
Cl&SS Dig Acei s Var 
Group 1 (captopril followed by digoxinl 
KNEF 
(%) 
Cl 
tIiter5imin per m’) 
PCWP 
(mm Hg) 
I i6M 
2 73M 
3 hlM 
4 33M 
5 XIM 
6 52M 
7 7lM 
x S9M 
9 SXM 
Mean 58 
LSD I 0 
DCM 
DCM 
CAD 
DCM 
DCM 
CAD 
CAD 
CAD 
DCM 
III 
IV 
III 
III 
IV 
III 
Ill 
ill 
III 
No 9 1.4 22 
No 13 I .1 25 
No 13 I .o 40 
No 13 I.4 40 
No 17 3. : 26 
No I? 2.1 30 
NO II I.6 18 
No I9 1.X 24 
No 15 I.8 28 
IS 1.X 29 
5 0-i 7 
Group 2 (digoxin followed by captopril) 
IO 69M CAD IV No No No I7 2.4 42 
II 49M CAD III Ye\+ No No 34 2.7 20 
I! 5YM CAD III No No No ?I 1.0 31 ‘.
I3 7lM DCM Ill No No No 40 2.j 44 
I4 4lM DCM Ill No Ye,<- No II I .9 35 
15 i4M DCM Ill No No Ye\ 25 I.6 30 
Ih 59M DCM III Ye\+ No Ye\ I9 I.5 40 
Mean 57 13 ?.I 35 
*SD 5 IO!: 0.3 x!. 
*All patients were receiving a constant dose of diuretic drug (furosemide): idiscontinued at least 7 days before study: idifferences between Groups I and 2 
(p < 0.05). Acei = angiotensin-converting enzyme inhibitors: CAD = coronary artery disease; Cl = cardiac index: DCM = dilated cardiomyopathy: Dig = 
digoxin; M = male: NYHA class = New York Heart Association functional class: PCWP = pulmonary capillary wedge pressure; KNEF = radionuclide ejection 
fraction: S Vas = \y\temic vasodilatora. 
Methods 
Patient selection. Patients enrolled in this study were 
among those admitted to Henry Ford Hospital between July 
1986 and May 1987 with a diagnosis of severe chronic heart 
failure due to ischemic or primary myocardial disease. All 
had normal sinus rhythm. 
Esclrrsion criteria WEW therapy with digitalis or systemic 
vasodilators other than nitrates 7 days before entering the 
study: heart failure resulting primarily from uncontrolled 
hypertension or congenital, valvular, pericardial, hypertro- 
phic or restrictive heart disease; myocardial infarction 
within the previous 2 months; history of atrial arrhythmias 
other than premature atrial complexes and significant pul- 
monary. renal, hepatic or hematologic disease. The protocol 
was approved by the Project Research and Human Rights 
Committee of Henry Ford Hospital. Participants were fully 
informed and provided written informed consent. 
Study patients (Table 1). The study group consisted of 16 
men with severe heart failure due to ischemic (7 patients) or 
dilated idiopathic (9 patients) cardiomyopathy. The mean 
age was 57 years (range 33 to 81). Prior medication and 
baseline hemodynamic characteristics are shown in Table 1. 
All had New York Heart Association functional class III or 
IV heart failure symptoms 30 to 60 days before admission 
and received a constant dose of diuretic drug in the hospital 
for several days before study. 
Study Protocol 
Baseline studies and measurements. To assure hemody- 
namic stability and prevent hemodynamic changes that may 
be induced by the instrumentation (20). the day before study. 
a balloon-tipped fiberoptic triple lumen thermodilution cath- 
eter (Swan-Ganz Oximetry, American Edwards; or Oximet- 
rix, Abbott Laboratories) was advanced into the pulmonary 
artery, and a short plastic cannula (3.OF. Cook) was inserted 
percutaneously into the radial artery. 
On the morning of the study, diuretic drugs were withheld 
and patients were maintained on a liquid diet. After hemo- 
dynamic stabilization (<IO% variability in cardiac index or 
pulmonary capillary wedge pressure). supine radionuclide 
ejection fraction at rest, heart rate and systemic arterial, 
pulmonary capillary wedge and right atrial pressures were 
determined, as previously described (211, and recorded on a 
multichannel physiologic recorder (Hewlett-Packard). Car- 
diac output was measured in triplicate by the thermodilution 
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Figure 1. Serial changes in cardiac index and pulmonary capillary 
wedge pressure in Group 1 (nine patients; captoprjl preceding 
djgoxin). *Analysis of variance for repeated measurements over 
time in response to the combination of captopril and digoxin; 
**comparison of the summary of mean hemodynamic values in each 
patient after the administration of captopril bolus injections (CB) 
and constant infusion compared with the sum of all mean values 
obtained after the additiop of digoxin to captopril. 
method (Oximeter cardiac output computer and Co Set, 
American Edwards). Mean arterial pressure, cardiac index, 
stroke work index and systemic vascular resistance were 
calculated using standard formulas. Blood samples were 
drawn, and serum digoxin, aldosterone concentration and 
plasma renin activity were determined by standard radioim- 
munoassay technique. Plasma norepinephrine measure- 
ments were available in only 12 patients, and were deter- 
mined with use of high performance liquid chromatography. 
Thirteen patients performed maximal exercise in a sitting 
position using a chair exercise bicycle (Pedalmate, Collins) 
with an electronic brake ergometer. The initial load of 25 W 
was increased by 2.5 W every 3 min. Heart rate, central 
hemodynamics and cardiac output were measured every 2 
min and at maximal exercise. When heart rate and pressures 
had returned to baseline, patients were considered to be at 
time 0. 
Drug intervention. The first nine consecutive patients 
studied constituted Group 1. Each patient received an initial 
dose of 1 mg of intravenous captopril (provided by E.R. 
Squibb & Sons Pharmaceutical). The dose was doubled 
approximately every 10 min until a total dose of 15 mg was 
given, unless the systolic blood pressure decreased to <SO 
mm Hg or the heart rate was increased to 120 beatsimin. The 
maximal dose of 15 mg was given to eight patients, and the 
remaining patient (Patient 8) received only 1 mg. All but one 
patient (Patient 8 receiving 1 mg/h) then received a continu- 
ous and constant infusion of captopril (6 mg/h) for the next 
consecutive 6 h. The initial dose of 1 mg was selected 
because it was reported (22) to cause a marked reduction 
(within minutes) in angiotensin II and angiotensin-converting 
Table 2. Rest Hemodynamics in Group l* 
Cl (litersimin 
HR (beatsimin) AP (mm Hg) PCWP (mm Hg) RA (mm Hg) per rn’) SW1 (gmim’) SVR (dynes,s.cm-‘) 
Pt B C CD B C CD B C CD B C CD B C CD B C CD B C CD 
1 98 92 86 98 83 90 22 20 18 4 12 8 2.4 2.0 2.5 25 19 29 1,635 1,535 1,396 
2 74 58 51 73 65 60 25 18 18 7 3 0 1.4 1.8 2.0 13 20 20 2,031 1,503 1,333 
3 102 89 91 87 67 65 40 25 24 15 13 II 1.0 2.5 3.0 7 I6 18 3,032 939 800 
4 110 95 96 78 73 90 40 32 28 14 15 I5 1.4 1.6 2.8 7 9 25 1,505 1,261 932 
5 84 77 84 93 90 83 26 16 IO 5 8 2 2.3 2.2 2.7 23 29 31 1,892 1,731 1,518 
6 94 84 14 74 69 58 30 26 24 I4 IO 7 2.2 2.2 2s 13 13 I2 1,069 913 912 
7 86 88 85 80 77 92 28 22 25 I2 14 14 1.6 1.5 I.8 14 13 19 1.935 2,016 2,066 
8 89 95 84 71 83 73 24 24 I7 IO 8 3 1.8 1.9 2.0 13 17 17 1,581 1,609 1,410 
9 62 57 84 104 65 95 28 12 14 5 4 6 1.8 1.6 2.4 32 20 32 1.980 1,294 1,230 
Mean 89 82 82 84 75 78 29 22 20 IO IO 7 1.8 1.9 2.4 I6 17 23 1,851 1,422 1,289 
+SD I5 I5 11 12 9 15 7 6 5 4 4 5 0.5 0.4 0.4 9 6 9 537 360 387 
p Valuet 0.02 NS 0.08 NS 0.003 0.0004 NS NS NS 0.02 NS 0.01 0.09 0.04 
p Value$ NS NS NS 0.02 0.003 0.03 0.008 
*Group 1 consisted of nine consecutive patients who first received captopril followed 2 h later by 1 mg of intravenous digoxin. Measurements obtained at 
baseline and 2 and 6 h after baseline in response to captopril alone and to the combination of captopril and digoxin. +p compared with baseline; fp compared with 
captopril. AP = mean systemic arterial pressure; B = baseline: C = captopril; CD = captopril and digoxin; HR = heart rate; Pt = patient; RA = mean right atrial 
pressure; SVR = systemic vascular resistance; SW1 = stroke work index; other abbreviations as in Table I. 
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Figure 2. Serial changes in cardiac index and pulmonary capillary 
wedge pressure in Group 2 (seven patients; digoxin preceding 
captopril). *Analysis of variance for repeated measurements over 
time: *“comparison of the summary of mean hemodynamic values in 
each patient after the administration of digoxin compared with the 
summary of all mean values obtained after the addition of captopril 
bolus injections (CB) and the constant infusion. 
enzyme levels. Given the fact that the bioavailability of oral 
captopril is 62% (Squibb Institute on Medical Research, data 
on file). the total I5 mg of intravenous bolus injections 
represented the usual oral dose of 25 mg. The infusion rate 
was calculated to produce the same blood level of captopril 
as produced by the total loading dose. The assumption made 
in the calculation included a volume of distribution of 0.2 
liter/kg for the central compartment. 2 liters/kg for the 
elimination phase and a total body clearance of 0.8 liter/kg 
per h (22). 
THY) hrs ufier the strrrt of the cnptopril ir[fir.sion. 1 mg of 
intravenous digoxin was given over 30 min. Rest hemody- 
namic values were obtained 5 to IO min after each bolus 
injection of captopril, serially thereafter for 6 h and at 8 h 
after the start of captopril infusion. Exercise hemodynamics 
were obtained at 2 h (immediately before digoxin adminis- 
tration) and 6 h. 
GlW1rp 2 cmsisted of SCIYJH consrcrrri~~c~ prrtients. Each 
patient received I mg of intravenous digoxin given over 30 
min. Three hours later. intravenous captopril was titrated in 
the same manner as for the first group. and a constant 
infusion continued for approximately 6 consecutive h. All 
seven patients tolerated the total I5 mg of captopril bolus 
in.jections and then a continuous infusion of 6 mgih. Rest 
hemodynamic values were obtained 5 to 10 min after each 
bolus injection of captopril and serially thereafter for 9 h. 
Exercise hemodynamic values were obtained at 2 and 6 h. 
In both groups, 2 cd 6 h ufter thefirst drug intrrvention, 
blood specimens were obtained for determination of norepi- 
nephrine concentration. In addition. at 6 h. digoxin and 
aldosterone concentrations and plasma renin activity were 
determined, and rest radionuclide angiography repeated. 
Statistical analysis. Values are represented as mean val- 
ues &SD. Sequential changes in hcmodynamic and hor- 
monal variables were analyzed using paired t tests, with 
Bonferroni’s multiple comparison adjustment. Probability 
(p) values ~0.05 were considered indicative of a meaningful 
Cl (literslmin 
Table 3. Rest Hemodynamics in Group 2” 
HR (beat\;min) At’ (mm Hg) PCWP (mm Hg) RA (mm Hg) per m’) SWI (g,m!m’) SVR (dynes,s,cm ‘j 
Pt B D DC B D DC B D DC B D DC B D DC B D DC 13 D DC 
I 0 95 x1 80 8s 86 90 42 24 26 IO I 0 IO 2.1 1.0 2.7 15 I7 30 I.1 I7 I.163 I.101 
II 96 95 96 IO1 90 86 20 15 11 6 4 8 7.7 3.1 3.4 !I 33 33 I..~10 1.047 865 
I? xx 82 Y? 80 75 72 32 73 20 I1 IO 6 2.0 1.9 3.0 IS 15 13 I .OY? 833 819 
I3 96 103 90 II5 I05 I12 44 !X 30 I3 IO x 22 1.6 3.4 23 16 42 I.701 l.3Y7 I.187 
I4 97 x7 73 82 x0 80 3.5 I2 II 6 ! 4 I .Y 3.0 3.4 I3 31 31 I.670 I.108 967 
IS 91 86 86 92 I IO IOX 30 26 I5 I6 IO I! I.6 2.1 2.0 I5 2X 30 1.X65 1.881 I.930 
I6 I06 YY I05 97 xx 91 40 30 31 Ii x 8 1.5 2.4 1.9 II I9 IS I.‘)31 I.159 I.385 
Mean 96 Yl 89 93 91 91 35 13 ?I II 8 8 7.1 2.6 2.8 I: 26 31 1.51’ 1.1’7 I.180 
&SD 6 x I 0 12 13 I3 8 7 x 1 3 3 0.4 0.4 0.7 - 6 I 0 74x 3A4 383 
p Value+ 0.0’) NS NS NS 0.004 0.0004 0.00’ 0.04 0.03 0.004 0.01 11.01 0.03 0.02 
p Value* NS NS NS NS NS NS NS 
“Group 2 consisted of seven consecutive patients who received digoxin first and captopril 3 h later. Measurements obtained at baseline and 2 and 6 h after 
baseline in response to digoxin alone and to the combination of digoxin and captopril. tp = compared with baseline: Zp = compared with digoxin. D = digoxin: 
DC = digoxin and captopril: other abbreviations as in Tables I and 2. 
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Table 4. Exercise Hemodynamics in Group I* 
CI (litersimin 
HR (beatsimin) AP (mm Hg) PCWP (mm Hg) RA (mm Hg) per m’) SW1 (g.m/m’) SVR (dynesscm-s) ET (s) 
Pt B C CD B C CD B C CD B C CD B C CD B C CD B C CD B C CD 
1 107 120 93 133 103 90 28 28 20 4 8 6 2.2 2.4 5.8 28 19 59 2,219 1,689 622 585 600 660 
2 ----_--_-___----___ _ ____ 
3 153 II5 104 97 91 100 38 34 34 I8 I? IO 1.7 2.7 3.0 9 I9 27 2,039 1,290 1,333 252 360 420 
4 120 I21 121 97 102 107 40 38 24 14 - IO 2.2 2.5 3.0 14 I8 27 1.274 - 1.069 450 562 835 
5 ----_-__-___------ - _ __-_ 
6 II7 105 IO5 II3 88 98 46 44 42 20 I4 14 2.7 4.5 3.1 21 25 23 1,466 688 1,111 I91 236 190 
7 I25 132 II8 118 107 II5 48 38 38 - 22 24 1.4 2.1 3.0 II I5 27 - 1,937 1.427 371 311 246 
8 98 106 100 109 77 102 30 36 20 4 I6 0 2.0 2.0 2.8 20 IO 33 2.159 1,251 1,500 200 252 276 
9 100 I35 120 122 95 103 30 I8 I8 5 0 0 2.5 3.6 3.8 26 27 37 1,547 886 897 246 375 489 
Mean II7 I19 109 II3 95 102 37 34 28 II 12 9 2.1 2.8 3.5 I8 19 33 1.794 1,290 1,137 328 385 445 
*SD I9 12 II I3 IO 8 8 8 IO 7 7 8 0.5 0.9 1.0 7 6 I2 417 470 312 147 144 236 
p Value? NS NS 0.01 NS NS 0.001 NS 0.03 0.02 0.01 NS 0.005 0.0002 0.02 0.06 NS 
p Value* 0.03 NS 0.07 NS NS 0.03 NS NS 
*Group I consisted of seven patients who received captopril first and I mg of intravenous digoxin 2 h later. Measurements obtained at baseline and 2 and 6 
h after baseline in response to captopril alone and to the combination of captopril and digoxin. tp compared with baseline; ip compared with captopril. ET = 
exercise time; other abbreviations as in Tables 1 and 2. 
change, whereas p values co.02 were considered statisti- 
cally significant. Repeated measures analysis of variance 
(ANOVA) was used to analyze for overall change across 
time (23). In addition, for each patient, the mean value for 
hemodynamic changes over the specified time was taken as 
the summary measure of response to digoxin or captopril 
given separately and compared with the summary measure 
in response to the combination of captopril and digoxin (24). 
Results 
Hemodynamic measurements at rest. Baseline compari- 
son of the two groups (Table 1) showed a higher pulmonary 
Table 5. Exercise Hemodynamics in Group 2* 
capillary wedge pressure and left ventricular ejection frac- 
tion in Group 2 than in Group 1 (p < 0.05 for both). No 
significant differences were noted between groups in regard 
to age, New York Heart Association functional class, prior 
medication, heart rate, systemic, pulmonary and right atria1 
pressures, cardiac index, stroke work index and systemic 
vascular resistance. 
The serial changes after captopril and digoxin adminis- 
tration in mean cardiac index and pulmonary capillary 
wedge pressure for all patients in Group I are shown in 
Figure 1. Captopril alone did not produce a significant 
change in cardiac index. The addition of digoxin to the 
CI (liters/m 
HR (beatslmin) AP (mm Hg) PCWP (mm Hg) RA (mm Hg) per m’) SW1 (g.m/m’) SVR (dynesscmm5) ET (s) 
Pt B D DC B D DC B D DC B D DC B D DC B D DC B D DC B D DC 
l0 -_-----_-_---_-___ - - ---- 
II 136 129 137 131 122 123 40 32 30 8 6 4 3.3 5.3 6.0 33 52 52 1,447 842 750 279 250 251 
I2 119 99 120 104 97 100 42 31 32 20 18 16 3.6 3.3 4.0 26 32 30 882 909 790 351 358 338 
13 108 108 100 122 138 142 48 46 38 I6 10 12 3.3 3.3 3.5 31 38 50 1,243 1,491 1,415 I51 207 225 
I4 127 129 127 I05 II3 I08 36 34 22 6 4 I 4.8 6.3 6.3 36 52 58 878 745 719 693 780 860 
15 106 99 II0 110 117 I38 36 36 40 28 16 22 1.1 3.2 2.6 II 36 32 3.051 1,293 1,788 147 248 320 
16 120 130 130 130 133 130 57 50 40 24 16 I6 2.9 3.1 3.9 24 27 37 1,266 1,307 1,049 364 417 550 
Mean II9 116 121 II7 120 124 43 38 34 17 I2 I2 3.1 4.0 4.4 27 39 43 1,461 1,098 1,085 331 377 424 
?SD I1 15 I4 I2 IS I78 8 7 96 8 I.2 I.4 I.5 9 IO I2 811 304 433 201 213 242 
p Value? NS NS NS NS 0.04 0.02 0.02 0.005 0.09 0.02 0.01 0.001 NS NS 0.07 0.06 
p Value* NS NS NS NS NS NS NS NS 
*Group 2 consisted of six patients who first received digoxin and captopril3 h later. Measurements were obtained at baseline and 2 and 6 h after baseline in 
response to digoxin alone and to the combination of digoxin and digoxin and captopril. tp compared with baseline; tp compared with captopril. Abbreviations 
as in Tables 1 to 4. 
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an increase in stroke work index of 44% (p = 0.01) a trend 
toward an increase in cardiac index of 24% (p = 0.09) and a 
decrease in pulmonary capillary wedge pressure of 11% (p = 
0.04). Although cardiac index increased with both captopril 
and digoxin, only with captopril did it reach statistical 
significance. This finding may have been related to a higher 
cardiac index observed at baseline in the patients in Group 2. 
The addition of captopril to digoxin resulted in a further 
increase in stroke work index and a decrease in pulmonary 
capillary wedge pressure, neither change reached statistical 
significance. 
Hemodynamic response to the combination of digoxin and 
captopril. The combination of digoxin and captopril (Fig. 3) 
had a greater hemodynamic effect compared with the effect 
of each drug given separately. At rest, pulmonary capillary 
wedge pressure decreased by 35% (p = O.OOOl), pulmonary 
artery pressure by 17% (p = 0.004) and systemic vascular 
resistance by 24% (p = 0.0002). Cardiac index increased by 
43% (p = 0.003) and stroke work index by 75% (p = 0.002). 
During exercise, pulmonary capillary wedge pressure de- 
creased by 24% (p = O.OOOl), right atria1 pressure by 40% (p 
= 0.006) and systemic vascular resistance by 29% (p = 
0.0009). Cardiac index increased by 61% (p = 0.0008) and 
stroke work index by 87% (p = 0.0004). The rest radionu- 
elide ejection fraction (Fig. 4) increased from 19 ? 9% to 24 
? 10% (p = 0.0007). 
Although an increase in maximal exercise time was noted 
in response to digoxin and captopril alone, this increase 
reached statistical significance only with the combination of 
digoxin and captopril (Fig. 3; Tables 3 and 4). 
Neurohormonal changes. At baseline, there was no sig- 
nificant difference between groups 1 and 2 in the increase of 
plasma norepinephrine concentration. The norepinephrine 
concentration did not change significantly in response to 
captopril; however, a significant decrease was observed 
after the administration of digoxin alone and when added to 
captopril (Fig. 5). The decline in norepinephrine concentra- 
tion correlated with the increase in stroke work index (r = 
0.90; p = 0.02) and cardiac index (r = 0.70; p = 0.09). 
In response to the combination of digoxin and captopril, 
the aldosterone concentration decreased from a mean of 22.2 
2 32.5 to 5.9 +- 3.2 pg/ml (p = 0.002). Plasma renin activity 
increased from 6.2 t 8 to 10.5 2 13 nglml per h (p = 0.004). 
The degree of increase in cardiac index in response to the 
combination of captopril and digoxin correlated with base- 
line levels of aldosterone (r = 0.81, p < 0.001) and plasma 
renin activity (r = 0.74, p < 0.0002). 
Digoxin concentrations. The serum digoxin concentration 
was below the limits of the assay in all patients during the 
control period. Six hours after the administration of 1 mg of 
digoxin, the serum digoxin concentration averaged 1.7 nglml 
(range 1 to 3). 
Discussion 
In this study of patients with severe heart failure in sinus 
rhythm, the short-term administration of captopril and dig- 
oxin given separately resulted in a significant and different 
hemodynamic improvement. Both drugs decreased pulmo- 
nary capillary wedge pressure; only digoxin increased car- 
diac and stroke work index. The combination of digoxin and 
captopril, however, produced an improvement in hemody- 
namic variables, both at rest and during maximal exercise, 
that was greater than that observed with either drug given 
alone. A significant decrease in plasma norepinephrine con- 
centration was associated only with digoxin administration. 
Acute hemodynamic effects of intravenous digitalis prepa- 
rations. This study is in general agreement with those of 
others (21,25-29) who found an increase in cardiac index and 
stroke work index associated with a decrease in pulmonary 
capillary wedge pressure when digitalis preparations were 
administered intravenously in patients with severe heart 
failure in sinus rhythm. However, when digitalis prepara- 
tions were administered to patients with heart failure whose 
hemodynamic status was normalized with diuretic drugs and 
vasodilators (21) or to normal subjects (3-5), no significant 
changes in hemodynamic variables were observed. 
It has been suggested that in patients with a lesser degree 
of heart failure (21) intravenous digoxin could increase 
systemic vascular resistance, thereby preventing an increase 
or even causing a decrease (7) in cardiac output. In contrast, 
in our patients with stable but very abnormal hemodynam- 
its, the administration of digoxin was associated with a 
reduction in systemic vascular resistance. Similarly, Mason 
et al. (30) observed a decrease in peripheral resistance in 
patients with severe heart failure in response to ouabain. 
Acute hemodynamic responses to captopril. Rademaker et 
al. (31) studied the effects of the addition of incremental 
doses of intravenous captopril in patients with chronic heart 
failure already receiving digoxin. Like others (l&17), they 
observed a reduction in systemic vascular resistance and 
pulmonary capillary wedge pressure associated with an 
increase in cardiac output. The maximal hemodynamic effect 
was obtained when a cumulative dose of 5 mg of intravenous 
captopril was reached. In our study, intravenous captopril 
alone, although decreasing pulmonary capillary wedge pres- 
sure and systemic vascular resistance, did not increase 
cardiac index. Because angiotensin enzyme inhibitors are 
not known to have a positive inotropic effect (32), it is 
possible that in some patients with heart failure already 
receiving digoxin, the addition of captopril may augment the 
inotropic effect of the glycoside by attenuating some of its 
peripheral vasoconstrictive effects (19). 
Comparison of digoxin and captopril. There are no previ- 
ously reported studies comparing the short-term hemody- 
namic effects of captopril and digoxin when administered 
separately. Although both digoxin or captopril decreased 
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pulmonary capillary wedge pressure at rest. only digoxin 
was associated with a significant increase in cardiac index. 
The combination of captopril and digoxin had a marked 
and, in some respects, additive effect in improving cardiac 
function both at rest and during exercise. This suggests that 
these agents achieve hemodynamic improvement by sepa- 
rate mechanisms: captopril by decreasing vascular resis- 
tance and digoxin by enhancing contractility. It is possible 
that in some patients, the salutary effects of digoxin can be 
potentiated by captopril, which blocks the activation of 
angiotensin II observed with digitalis preparations (19). That 
the effects were not always additive suggests that when 
hemodynamic variables or neurohormonal abnormalities are 
attenuated by a drug, one is less likely to observe significant 
changes in response to the addition of a second drug. 
minimize these variations, patients underwent instrumenta- 
tion 1 day before study, vasoactive substances were with- 
held and each patient was placed on a clear liquid diet. 
It is not known if the short-term additive salutary effects, 
including the increase in exercise time, observed with the 
combination of digoxin and captopril are sustained. Packer 
et al. (40) reported that the effect of the first dose of captopril 
is usually sustained, but in some patients this effect may 
initially be attenuated or delayed. This triphasic response 
suggests that a complex relation may exist between the early 
and late hemodynamic effects of vasoactive drugs in patients 
with heart failure. 
Only two studies hulle compured the long-turn rffeects of 
captopril und digoxin. Alicandri et al. (33) using isometric 
exercise, examined the effects of captopril and digoxin in 
patients with chronic heart failure and concluded that both 
drugs are beneficial. Similarly, in a multicenter trial (18) 
comparing the effects of captopril and digoxin in patients 
with moderate heart failure, digoxin alone caused an in- 
crease in ejection fraction, compared with that obtained with 
captopril and placebo. without significantly increasing exer- 
cise time or improving functional class. Captopril increased 
exercise tolerance, in comparison with results after placebo, 
without affecting ejection fraction. 
Clinical implications. In this group of patients with severe 
heart failure, the short-term administration of digoxin and 
captopril independently caused salutary hemodynamic ef- 
fects. The combination of captopril and digoxin had an 
adjunctive effect in improving cardiac function at rest and 
during exercise. Further clinical studies appear warranted to 
determine whether these short-term effects are sustained. 
We express our appreciation to Elaine Bust. for secretarial assistance in the 
preparation of this report. 
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